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The completion of the Human Genome Project in 2003
continues to raise expectations on near-term applications
of human genome discoveries in personalized disease
prevention, especially in the area of common chronic dis-
eases (1,2). In fact, almost daily we are confronted with
stories of scientific discoveries of human genetic variants
that are suggested to affect our risks for one or more of
the major common chronic diseases. (See Table 1 for an
illustrative sample of news stories published online dur-
ing December 2004 [3].) Yet the immediate significance
of most of these discoveries remains elusive. Despite the
scientific excitement and the predictions for personalized
prevention and drug treatment, the promise of human
gene discovery for health promotion and disease preven-
tion is yet to be fulfilled (4).
Increasingly, public health practitioners from academic,
government, and other organizations have taken a proac-
tive leadership role in assessing the relevance of this tech-
nology to population health and to community-based inter-
ventions (a new field often referred to as public health
genetics, or genomics) (5). This issue of Preventing Chronic
Disease contains several articles illustrating various
processes developed and applied by schools of public
health and state health departments to evaluate the role
of genomics and its relevance to the prevention of chronic
diseases in the population (6-11).
Johnson et al (6) demonstrate the feasibility and suc-
cess of using family history as a simple genomic tool to
inform and motivate high-risk families to make long-
term lifestyle behavior changes for preventing a variety
of chronic diseases. Annis et al (7) show that existing
population-based databases contain valuable genomic
information and can serve as a reliable source for chron-
ic disease program recommendations for early detection,
prevention, and risk assessment. Irwin et al (8) examine
the genomic content of state Comprehensive Cancer
Control programs and show that many states have
genomic components in their written plans. Importantly,
about 67% of programs that included family history in
their plans have already begun implementing their stat-
ed goals. Harrison et al (9) describe a process for syn-
thesizing genomics information and for sharing knowl-
edge and lessons learned. Novel educational approaches,
such as the one presented by Theisen et al (10), and
innovative training tools, such as those highlighted by
Bodzin et al (11), will be crucial in efforts to provide con-
tinuing education for the public and health care profes-
sionals. A central theme in all of these papers is the
importance of family history as a tool for chronic disease
prevention and health promotion.
Why should public health focus on family history in the
genomics era?
In November 2004, the United States Surgeon General
launched a public education campaign urging all citizens
to know their family medical history and to discuss it with
health care providers using an online family history col-
lection tool (12). With all the excitement about genomics,
one may wonder why we are still using an old-fashioned
tool such as family history (13). Nonetheless, several basic
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facts about family history make it ideal for use in public
health practice:
1) A history of one or more chronic diseases is common
in the population, although awareness of the details and
accurate reporting of the disease may be suboptimal.
2) Family history is the most consistent risk factor for
almost all human diseases across the lifespan (14). Thus,
the presence of a disease in a family, especially among
first-degree relatives, increases the risk for that disease.
3) Family history reflects the complex interaction among
many shared genes, shared behaviors, shared cultures,
and shared environments among families, all of which
could also be disease risk factors. In fact, only a small frac-
tion of people with family history of a common chronic dis-
ease have a “genetic disease” (with high lifetime risk of dis-
ease). A total of 188 such diseases have been identified as
of 2004, accounting for a relatively small burden of chron-
ic disease (15). Most people with family history of a disease
have a moderately increased risk of the disease.
4) Although family history cannot be changed, knowl-
edge of it provides an opportunity to personalize and tar-
get our myriad disease prevention and health promotion
messages (12,16).
5) Today, family history is the best genomic tool avail-
able, and compared with other genetic tests, it can be rel-
atively inexpensively collected.
Although eliciting family history should be a routine
component of patient medical records and encounters with
health care providers, the completeness of such informa-
tion and its use in practice are less than optimal. Despite
the implications of family history for public health, the
public’s knowledge, attitudes, and behaviors related to
family history have some way to go. In a recent national
survey of 4345 adults, the Centers for Disease Control and
Prevention (CDC) found that although most respondents
(97%) considered knowledge of family history either very
important or somewhat important to their personal
health, a strikingly smaller proportion (30%) reported
actively engaging in collection of information to develop a
family health history (17). Routine collection and use of the
family history by clinicians remains suboptimal. Acheson
et al have shown that family history is discussed in only
half of new visits to primary care physicians and 22% of
follow-up visits. Also, the average duration of the family
history discussion is only 2.5 minutes, focusing mostly on
psychosocial and not health-related issues (18). More
recently, Walter et al reviewed lay understanding of famil-
ial risk for common chronic diseases and how each person’s
sense of disease vulnerability depends not only on family
history but also on personal models of disease causation
and inheritance (19). These findings underscore the need
for more public and health provider education to improve
the effectiveness of using family history as a risk commu-
nication tool for personal health and disease prevention.
Despite the importance of family history for health pro-
motion, our public health strategy in preventing common
chronic diseases continues to be a one-size-fits-all
approach to promoting healthy lifestyles in the population
at large. Most people do not get enough physical activity,
are overweight, and do not adhere to health screening 
recommendations. With development and validation of the
right family history tools, public health can begin to 
develop, test, and apply personalized prevention 
messages. Because a large fraction of the population has a
family history of one or more common diseases, 
augmenting and not replacing the population approach to
prevention with an approach focused on higher-risk fami-
lies may help achieve overall population health goals. For
example, we know from population studies conducted in
Utah that 14% of families have almost 72% of the burden
of early heart disease (under 50 years of age) and 48% of
the burden of all heart disease in the whole population
(20). A distinct advantage of a family-centered approach to 
prevention is that it does not focus exclusively on genetic
factors but works within an overall framework of biologic
and sociocultural relationships to effect behavioral change
and risk factor reduction. As discussed in this issue by
Johnson et al (6), family history can begin to build a bridge
between the one-size-fits-all approach to prevention and
the one-person-at-a-time approach to genetics.
What are the emerging public health priorities in
genomics?
Three emerging priorities for public health action in
genomics highlighted in this issue of Preventing Chronic
Disease are 1) the conduct and support of population-based
research and databases in genomics and health; 2) the
development of the evidence base for genomic applications
in health promotion and disease prevention; and 3) the
assurance of an adequate public health capacity in
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a road map for long-term translation of human genome
discoveries into chronic disease prevention and health pro-
motion across the lifespan.
1) Conduct and support of population-based
research and databases on genomics and health.
Generally, additional public health research is needed to
asses the impact of the thousands of genetic variants (and
their interactions with modifiable risk factors) on the bur-
den of chronic diseases (incidence and prevalence as well
as morbidity, disability, and mortality). Although
gene–disease associations continue to be investigated in
the context of family studies, association studies using
mostly case-control designs are becoming more common.
As shown in Table 2 for a sample of common chronic dis-
eases, the number of published epidemiologic articles on
gene–disease association is increasing over time. These
data are derived from the Genomics and Disease
Prevention Information System (GDPInfo) (21), an online
searchable and continuously updated information system
developed by the CDC. Between October 1, 2000, and
December 30, 2004, GDPInfo captured records of 13,858
published epidemiologic articles on genes and disease out-
comes. The population-level implications of findings from
many such studies are unclear. Often, the potential impor-
tance of a reported association is impossible to evaluate
because basic population-based genotype prevalence data
are not available. The CDC and many collaborators in the
Human Genome Epidemiology Network (HuGE Net) are
currently developing methodologic guidance and system-
atic reviews for integrating data from these studies and
developing inference for research, policy, and practice (22).
Another example of the use of national surveys is the
existing DNA repository containing specimens from more
than 7000 participants in the second phase of National
Health and Nutrition Examination Survey (NHANES) III
(1991–1994). The CDC determined the prevalence of gene
variants associated with hereditary hemochromatosis
(23,24). The CDC in collaboration with the Juvenile
Diabetes Research Foundation and others created the type
1 diabetes DNA repository to study genetic risk factors for
sequelae of type 1 diabetes (25-27). Also, the CDC devel-
oped a DNA repository as part of the population-based
National Birth Defects Prevention Survey (28).
In addition to national surveys, state public health pro-
grams can provide valuable population data to assess the
impact of genes on the burden of chronic disease. An exam-
ple of state-based data collection for chronic disease is the
cancer registries that are a component of state-based com-
prehensive control programs (see Irwin et al in this issue).
These registries can truly provide a population-level
assessment of the impact of family history and individual
genes on the burden of cancer in the United States.
2) Development of the evidence base for genomic
applications in health promotion and disease pre-
vention. Public health is beginning to evaluate the added
value of using genetic tests as tools for disease prevention.
For decades, public health practice has downplayed the
“high risk” model of prevention in favor of a population
approach, which may not benefit most individuals but can
have a large impact on the burden of disease (29,30). For
example, a small downward shift in mean serum choles-
terol distribution could reduce the burden of coronary
heart disease in the population more than treating people
with high cholesterol levels, since most of the burden of
heart disease occurs among persons with values in the nor-
mal range (29). As the discussion of family history illus-
trates, we can combine a high risk strategy with a popula-
tion strategy to achieve overall public health goals.
Nevertheless, the use of individual genes as risk factors for
disease or the use of a combination of genetic variants
along biologic pathways (so-called genomic profile) for test-
ing for chronic disease susceptibility should be quantita-
tively evaluated for its potential impact on individuals and
the population (31,32). In general, existing quantitative
evaluations of combinations of genetic variants and their
expressions are still in the theoretical realm and are based
on many assumptions that have not been validated.
As in other areas of health practice, public health is
becoming the convener of multidisciplinary deliberations
needed to determine the role, if any, of genomics informa-
tion, above and beyond a population approach to the 
prevention of chronic diseases (e.g., smoking control 
programs, diet, physical activity, early detection 
programs). The recent surge of direct-to-consumer 
marketing of genetic tests, such as genomic profiles for
susceptibility to cardiovascular disease and bone health
(33) and for testing for breast and ovarian cancer (34), will
increasingly necessitate a public health response for build-
ing the evidence base for use of genomic applications in
population health and for measuring the impact of test
marketing on consumers’ and providers’ knowledge, 
attitudes, and behaviors.
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For the past five years, the CDC and many collaborators
have developed model approaches for obtaining and syn-
thesizing available information on genetic tests. The
Foundation for Blood Research developed key data ele-
ments needed for genetic tests by intended use and applied
a model approach to five conditions (35). The CDC and
many partners are currently exploring the development of
a more sustainable public–private partnership process to
summarize evidence and identify gaps in knowledge to
stimulate further research. In addition, public health
assessment will be needed to monitor current and future
levels of use of genetic tests, as well as knowledge, atti-
tudes, and behaviors of consumers and health care
providers. A population-based approach in collecting valid
clinical and laboratory data will ensure that consumers,
practitioners, and policy makers have access to timely and
current information on genetic tests and their impact on
the public’s health. These efforts will also allow a smoother
integration of validated genetic tests into practice.
One example of a public health assessment in genomics
is a 1997 expert panel workshop jointly held by the
National Institutes of Health (NIH) and the CDC to
explore issues on population screening for iron overload
due to hereditary hemochromatosis (a small but preventa-
ble cause of multiple chronic diseases including heart dis-
ease, liver cancer, diabetes, and arthritis) (36). This col-
laboration led to the identification of important gaps in
research, funding of further studies, and implementation
of a nationwide physician training program that promotes
early detection of hemochromatosis (37).
3) Assurance of an adequate public health capaci-
ty in genomics. Clearly, the integration of genomic infor-
mation into practice and programs requires resources, a
competent workforce, a robust public health system that
can address health disparities, and an informed public.
Educational and planning resources for public health
genomics have been developed over the past three years
(11). The Association of State and Territorial Health
Officials’ guide to genomics for public health practitioners
(38) and the Web-based introduction to genomics (Six
Weeks to Genomic Awareness) developed by the University
of Michigan (39) are examples of the available resources.
Another useful state policy guide for genomics and chron-
ic diseases was developed by the Partnership for
Prevention™, a public–private coalition focused on disease
prevention and health promotion (40).
A 2003 report by the Institute of Medicine identified
genomics as one of the eight crosscutting priorities for the
training of all public health professionals in the 21st cen-
tury (41). In October 2003, the Association of Schools of
Public Health administered an online survey to represen-
tatives of all 33 accredited U.S. schools of public health.
The survey provided a baseline assessment of the extent to
which the schools were offering curriculum content in the
eight areas recommended by the Institute of Medicine,
including genomics (42). Although 52% of the schools offer
courses in genomics, only 15% of the schools require
genomics to be part of their core curriculum, clearly the
lowest figure for all eight crosscutting areas (highest was
policy with 79%), indicating a definite need for improved
integration of genomics into public health education (42).
Over the past five years, the CDC has promoted the inte-
gration of genomics across all public health functions,
including training and workforce development. In collabo-
ration with many partners, the CDC hosted the develop-
ment of public health workforce competencies in genomics
(43), established three Centers for Genomics and Public
Health at schools of public health to develop training (44),
provided funding and technical assistance to state and
local health departments (45), and actively engaged in
offering training and career development opportunities in
genomics and public health. As discussed by Dr Bill Roper,
previous Dean of the School of Public Health at the
University of North Carolina at Chapel Hill, at the CDC
public health genomics symposium in May 2003, genomics
is becoming an integral component of the concept of “pub-
lic health preparedness” in the 21st century (46).
Conclusion
Although a nascent field, the application of genomics to
chronic disease prevention and health promotion is
already occurring at the state and local levels. Success in
this endeavor will require building appropriate capacity
and maintaining a skilled public health workforce compe-
tent in the evaluation and use of genomic information for
preventing common chronic diseases. Of equal importance
is the development of innovative tools and evidence-based
processes that allow the differentiation between genomic
technology that is ready for use in population health and
technology that is not ready for prime time. Health policies
need to be developed to ensure the appropriate use of
genomic information for health promotion while avoiding
psychosocial and financial harms to individuals and 
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Preventing Chronic Disease, we believe that the contin-
ued leadership and collaboration among schools of pub-
lic health, state health departments, and other public
health partners will take us a long way to ensure that
human genomic information will be used for preventing
chronic diseases and promoting health in individuals,
families, and communities.
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Tables
Table 1. Examples of News Stories on Human Genome Discoveries Relevant to Common Chronic Diseasesa
Faulty gene signaling linked to Crohn’s HealthDay News Dec 28, 2004
Genetic difference at opiate receptor gene affects a
person’s response to alcohol Medical News Today Dec 15, 2004
Important discovery of gene involved in breast and prostate cancer PR Newswire Dec 15, 2004
Mutant gene linked to treatment-resistant depression NIH news release Dec 14, 2004
Molecular test can predict both the risk of breast cancer recurrence and 
who will benefit from chemotherapy NCI news release Dec 10, 2004
Important genetic risk factor for amyotrophic lateral sclerosis News-Medical.Net Dec 6, 2004
Association of vitamin D receptor gene polymorphisms with childhood 
and adult asthma RedNova News Dec 2, 2004
aWeb-based stories posted on the CDC Genomics & Health Weekly Update, December 2004. Available from: www.cdc.gov/genomics/update/current.htm.
NIH indicates National Institutes of Health; NCI indicates National Cancer Institute.
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Table 2. Number of Gene–Disease Association Studies Reported in the Medical Literature, by Year and Disease, CDC
Genomics and Disease Prevention Information System, 2001–2004a
Coronary heart disease (and stroke) 197 205 262 238
Diabetes 128 154 156 165
Breast cancer 61 111 136 146
Colorectal cancer 53 55 46 70
Lung cancer 35 52 60 55
Alzheimer’s 88 100 111 145
Asthma 38 40 49 71
aSearch was conducted on December 30, 2004, at http://www2a.cdc.gov/genomics/GDPQueryTool/frmQueryAdvPage.asp.
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No. published articles
Disease 2001 2002 2003 2004